Protocol Ledger

NCT07001748 · Phase II/III · RECRUITING

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Interventional Phase II/III clinical trial protocol NCT07001748 sponsored by ECOG-ACRIN Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-24 Enrollment: 148 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07001748
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)148 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07001748
Protocol FieldVerified Registry Value
NCT IdentifierNCT07001748
Consolidated Lead SponsorECOG-ACRIN Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment148 participants (ESTIMATED)
Registered Start Date2025-10-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI